BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25529740)

  • 1. Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
    An XD; Liu H; Xu ZL; Jin Y; Peng X; Yao YM; Geng M; Long YQ
    Bioorg Med Chem Lett; 2015 Feb; 25(3):708-16. PubMed ID: 25529740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.
    Wang Y; Xu ZL; Ai J; Peng X; Lin JP; Ji YC; Geng MY; Long YQ
    Org Biomol Chem; 2013 Mar; 11(9):1545-62. PubMed ID: 23188156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
    Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
    ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
    Liu TC; Peng X; Ma YC; Ji YC; Chen DQ; Zheng MY; Zhao DM; Cheng MS; Geng MY; Shen JK; Ai J; Xiong B
    Acta Pharmacol Sin; 2016 May; 37(5):698-707. PubMed ID: 27041462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors.
    Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5093-7. PubMed ID: 25282552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Yang Y; Zhang Y; Yang L; Zhao L; Si L; Zhang H; Liu Q; Zhou J
    Bioorg Chem; 2017 Feb; 70():126-132. PubMed ID: 28043720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
    She N; Zhuo L; Jiang W; Zhu X; Wang J; Ming Z; Zhao X; Cong X; Huang W
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3351-5. PubMed ID: 24951334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
    Zhang D; Zhang X; Ai J; Zhai Y; Liang Z; Wang Y; Chen Y; Li C; Zhao F; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2013 Nov; 21(21):6804-20. PubMed ID: 23993328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.
    Zhou S; Liao H; Liu M; Feng G; Fu B; Li R; Cheng M; Zhao Y; Gong P
    Bioorg Med Chem; 2014 Nov; 22(22):6438-52. PubMed ID: 25438768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met.
    Damghani T; Moosavi F; Khoshneviszadeh M; Mortazavi M; Pirhadi S; Kayani Z; Saso L; Edraki N; Firuzi O
    Sci Rep; 2021 Feb; 11(1):3644. PubMed ID: 33574356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.
    Park BS; Al-Sanea MM; Abdelazem AZ; Park HM; Roh EJ; Park HM; Yoo KH; Sim T; Tae JS; Lee SH
    Bioorg Med Chem; 2014 Aug; 22(15):3871-8. PubMed ID: 24997577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
    Qi B; Mi B; Zhai X; Xu Z; Zhang X; Tian Z; Gong P
    Bioorg Med Chem; 2013 Sep; 21(17):5246-60. PubMed ID: 23838381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors.
    Zhang L; Zhang B; Zhao J; Zhi Y; Wang L; Lu T; Chen Y
    Eur J Med Chem; 2017 Sep; 138():942-951. PubMed ID: 28755635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
    Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
    Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
    Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H
    Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.
    Jiang X; Liu H; Song Z; Peng X; Ji Y; Yao Q; Geng M; Ai J; Zhang A
    Bioorg Med Chem; 2015 Feb; 23(3):564-78. PubMed ID: 25537530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
    Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
    Trani G; Barker JJ; Bromidge SM; Brookfield FA; Burch JD; Chen Y; Eigenbrot C; Heifetz A; Ismaili MHA; Johnson A; Krülle TM; MacKinnon CH; Maghames R; McEwan PA; Montalbetti CAGN; Ortwine DF; Pérez-Fuertes Y; Vaidya DG; Wang X; Zarrin AA; Pei Z
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5818-5823. PubMed ID: 25455497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.